Journal article
A unique recombinant fluoroprobe targeting activated platelets allows in vivo detection of arterial thrombosis and pulmonary embolism using a novel three-dimensional fluorescence emission computed tomography (FLECT) technology
B Lim, Y Yao, ALI Huang, ML Yap, U Flierl, J Palasubramaniam, MTK Zaldivia, X Wang, K Peter
Theranostics | IVYSPRING INT PUBL | Published : 2017
DOI: 10.7150/thno.18099
Abstract
Progress in pharmaceutical development is highly-dependent on preclinical in vivo animal studies. Small animal imaging is invaluable for the identification of new disease markers and the evaluation of drug efficacy. Here, we report for the first time the use of a three-dimensional fluorescence bioimager called FLuorescence Emission Computed Tomography (FLECT) for the detection of a novel recombinant fluoroprobe that is safe, easily prepared on a large scale and stably stored prior to scan. This novel fluoroprobe (Targ-Cy7) comprises a single-chain antibody-fragment (scFvTarg), which binds exclusively to activated-platelets, conjugated to a near-infrared (NIR) dye, Cy7, for detection. Upon mo..
View full abstractGrants
Funding Acknowledgements
The authors would like to thank Mr Cameron Nowell for his technical support in the running of the FLECT, CT and IVIS scanners. This work is funded by the National Health and Medical Research Council (NHMRC). K.P is a NHMRC Principal Research Fellow. M.L.Y is supported by an Australian Postgraduate Award (APA) scholarship. A.L.H. is supported by the National Heart Foundation Postgraduate scholarship. X.W. is National Heart Foundation Postdoctoral Fellow.